PN - Peptide T

Home - Links - Research - Peptide T
PN

Peptide T study, HIVCare.org
'gp 120, a protein that studs the surface of the HIV virus, breaks off and attaches itself to cells of the central and peripheral nervous systems, causing a variety of problems including dementia and peripheral neuropathy. Peptide T is identical to a portion of that surface molecule'.

Peptide T®: AIDS Trial To Begin
"Peptide T® is suddenly very promising," said Dr. Gifford Leoung, MD, Medical Director of HIVCare and principal investigator of the trial. "We are hopeful that Peptide T's® viral entry inhibition will emerge as a new, preferred treatment for people with HIV and AIDS,"

PEPTIDE - T Fact sheet
'Neurological symptoms: Several small studies have shown that Peptide- T may be most promising as a treatment for cognitive deficits and painful peripheral neuropathy'.

Peptide T
'MacFadden reported that of 9 individuals with HIV-related peripheral neuropathy treated with Peptide T (subcutaneously at an initial dose of 10 mg daily, with 2 patients tapered to 2.5 mg in order to determine the minimal effective dose), all experienced either complete or subjectively significant resolution of lower limb pain, with effects being noticed as early as two days after initiation of treatment'.

Peptide T and HIV, IBIS
'An exciting new and emerging area for the development of anti-viral therapies comes from the realization that viruses use specific cell surface molecules as their targets of initial attachment'.

Peptide T: A GP-120 Blocking Protein, Emily Kane, N.D.
'Peptide T is an analog of the neuropeptide VIP and the HIV gp-120 protein, which binds to cells. It is being produced for the clinical trials by Peninsula Laboratories and is currently licensed to Advanced Peptides (a European firm) and the US-based Reed-McFadden.'